The efficacy and safety of eravacycline in the treatment of patients with pneumonia in respiratory departments: A real-world multicenter retrospective study.

INTRODUCTION

Eravacycline (ERV), a novel fluorocycline antibiotic, demonstrates broad-spectrum activity against multidrug-resistant (MDR) pathogens. This multicenter retrospective study evaluates the real-world clinical effectiveness of ERV in treating various infections of the patients hospitalized in the respiratory departments.

METHODS

We analyzed 113 adult patients treated with ERV from respiratory departments in China, examining antimicrobial susceptibility profiles and serial laboratory parameters during therapy. Microbiological and clinical outcomes were systematically evaluated at treatment completion and 30-day follow-up. Subgroup analyses focused on Acinetobacter baumannii and Klebsiella pneumoniae infections.

RESULTS

ERV exhibited 87.6% clinical efficacy and 85.8% microbiological eradication rate, accompanied by an 85.0% 30-day survival rate. The antibiotic maintained robust activity against MDR pathogens, particularly A. baumannii (n = 51) and K. pneumoniae (n = 27). Adverse events occurred in only 1.8% (2/113) of cases. Clinical outcomes showed no statistically significant differences between monotherapy (n = 70) and combination regimens (n = 43).

CONCLUSION

This real-world evidence confirms ERV as an effective and well-tolerated therapeutic option for managing patients in the respiratory departments, particularly those caused by MDR Gram-negative pathogens. The comparable efficacy of monotherapy and combination approaches warrants further investigation.